Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Antiviral Agents

Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir

Belén Borrego, Ana I. de Ávila, Esteban Domingo, Alejandro Brun
Belén Borrego
aCentro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana I. de Ávila
bCentro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esteban Domingo
bCentro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid, Spain
cCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro Brun
aCentro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alejandro Brun
DOI: 10.1128/AAC.00669-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Effect of favipiravir treatment on viral yields in cell culture. Vero cells were pretreated overnight with the indicated concentrations of drug and then infected with RVFV 56/74 at a MOI of 0.1 PFU/cell. Infection proceeded for 72 hpi in the presence of the same concentration of favipiravir. Results are shown either as 50% tissue culture infective dose (TCID50) per milliliter (continuous line; left y axis) or as percentages of RVFV titer with respect to the one obtained in untreated cells (dashed line; right y axis). Values under the limit of sensitivity of the assay (estimated to be 10, indicated with a grid line) were arbitrarily represented as 2. Red line indicates 50%. Error bars denote standard deviation (SD).

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Serial passages of RVFV in Vero cells in the absence or presence of favipiravir. (A) Viral titers of RVFV after each passage in the absence or presence of different concentrations of favipiravir (T-705) as indicated. For concentrations higher than 80 μM, only 3 passages were performed. Viral titers in the supernatant of infected cells were determined at 72 hpi. Error bars denote SD. (B) Comparison of the viral titers obtained from virus recovered after passage 8 (previously propagated or not with 40 μM favipiravir) and those of parental RVFV 56/74 in the presence of a 5 to 80 μM range of favipiravir concentrations. Titers are represented as percentages with respect to those obtained without drug. Red line indicates 50%. Error bars denote SD. Asterisks denote a P value ≤ 0.0001 (p8-no Fav or RVFV 56/74 versus p8-40μM Fav; Student's t test). (C) Lack of detectable infectivity after blind passages as a criterion for RVFV extinction. Cell culture supernatants from passages carried out in the presence of favipiravir where no cytopathic effect (CPE) was observed (Fig. 2A; samples whose titers were below the limit of sensitivity of the assay) were subjected to additional passages (up to five) in the absence of drug. Original samples are named according to their passage number in the presence of the indicated favipiravir concentration (in μM). Flattened columns indicate no CPE detection; lifted columns indicate evident CPE.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Effect of favipiravir in the specific activity of RVFV. (A) Viral titers of RVFV after each passage (n = 4) in the absence (white columns) or presence (black columns) of 40 μM favipiravir (redrawn from data shown in Fig. 2A). (B) Quantification by qRT-PCR (in triplicate) of RNA extracted from the supernatants of untreated (white columns) or 40 μM favipiravir-treated (black columns) Vero cells after each passage (n = 4). (C) Specific infectivity upon passage of RVFV in the absence (open symbols) or presence (closed symbols) of 40 μM favipiravir. Values correspond to the ratio between infectivity (A) and the amount of viral RNA (B). Error bars denote SD. Statistically significant differences are indicated by asterisks (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005; ****, P ≤ 0.0001; Student's t test).

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Distribution of mutations among individual clones. Plot of the distribution of the number of mutations per molecular clone in the RVFV populations passaged in the absence or presence of 40 μM favipiravir.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Mutational spectrum induced by favipiravir on RVFV. Matrices of mutation types found in the glycoprotein Gc-coding region of RVFV passaged 4 times in Vero cells in the absence or presence of 40 μM favipiravir. The boxes below each matrix quantify the mutational bias according to the ratio shown on the left.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Mutant spectrum analysis by molecular cloning and Sanger sequencing of the glycoprotein Gc-coding region of RVFV passaged 4 times in Vero cells

    RVFV populationaNo. of nucleotides analyzed (clones/haplotypes)bNo. different (total) mutationscMinimum mutation frequencydMaximum mutation frequencyeNo. different synonymous (nonsynonymous) mutationsTotal no. synonymous (nonsynonymous) mutations
    56/74 p4, no drug31,610 (29/21)53 (375)1.7 × 10−31.2 × 10−248 (5)354 (21)
    56/74 p4 + favipiravir31,610 (29/29)138 (348)4.4 × 10−31.1 × 10−285 (53)284 (64)
    • ↵a The origin and passage history of the viral populations analyzed is described in Fig. 2 and in Materials and Methods.

    • ↵b The genomic region analyzed spans residues 2110 to 3199 of the glycoprotein Gc-coding region; the residue numbering is that of the SA-75 genome. The values in parenthesis indicate the number of clones analyzed followed by the number of haplotypes (number of different RNA sequences).

    • ↵c The number of different and total mutations were counted relative to the consensus sequence of the corresponding population. Different and total mutations were used to calculate the minimum and maximum mutation frequency, respectively.

    • ↵d Data represent the average number of different mutations per nucleotide in the mutant spectrum relative to the consensus sequence of the corresponding population. The results indicate a significant 2.5-fold increase of minimum mutation frequency associated with replication in the presence of favipiravir (P < 0.0001; χ2 test).

    • ↵e Data represent the average number of total mutations per nucleotide in the mutant spectrum relative to the consensus sequence of the corresponding population.

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Table S1

      PDF, 198K

PreviousNext
Back to top
Download PDF
Citation Tools
Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir
Belén Borrego, Ana I. de Ávila, Esteban Domingo, Alejandro Brun
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00669-19; DOI: 10.1128/AAC.00669-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir
Belén Borrego, Ana I. de Ávila, Esteban Domingo, Alejandro Brun
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00669-19; DOI: 10.1128/AAC.00669-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

favipiravir
Rift Valley fever virus
T-705
lethal mutagenesis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596